Non-invasive growth RSP Systems is pursuing non-invasive glucose sensing with a broad digital health impact, presenting a compelling opportunity to partner with medical device distributors, healthcare providers, and payer networks looking to expand non-invasive monitoring capabilities.

Strategic partnerships Recent and historical collaborations with Trumpf and Brenmiller Energy suggest openness to co-developments and distribution deals; target potential OEMs, laser/electronics integrators, and energy/storage firms seeking advanced sensing integrations.

EU funding leverage Horizon 2020 backing and a track record of European equity funding indicate strong credibility and potential for grant-backed pilots; sales motions can emphasize co-funded trials, regulatory support, and regional deployments within Europe.

Regulatory readiness ISO 13485 certification shows a focus on medical device quality systems; approach large health systems and contract manufacturers that require compliant development, manufacturing, and quality processes for rapid scale.

Emerging wearables RSP is developing wearable glucose sensing and Raman-based devices, signaling an avenue to pitch to diabetes care programs, remote patient monitoring platforms, and consumer-health ecosystems seeking advanced, user-friendly monitoring options.